Hoche Partners Pharma Amends Procaps Group Stake
Ticker: PRCWF · Form: SC 13D/A · Filed: Oct 10, 2024 · CIK: 1863362
Sentiment: neutral
Topics: ownership-change, sec-filing, amendment
Related Tickers: PROC
TL;DR
Hoche Partners Pharma filed an amendment on their Procaps Group stake. Watch for potential moves.
AI Summary
Hoche Partners Pharma Holding S.A. filed an amendment (No. 10) to its Schedule 13D on October 10, 2024, regarding its holdings in Procaps Group, S.A. The filing indicates a change in the reporting person's beneficial ownership of Procaps Group's ordinary shares.
Why It Matters
This amendment signals a potential shift in the ownership structure or strategy of Procaps Group, S.A., which could impact its stock price and future business decisions.
Risk Assessment
Risk Level: medium — Amendments to Schedule 13D filings often indicate significant changes in beneficial ownership, which can lead to increased volatility and strategic shifts for the company.
Key Numbers
- 10 — Amendment Number (Indicates this is the tenth update to the filing.)
Key Players & Entities
- Hoche Partners Pharma Holding S.A. (company) — Filing person
- Procaps Group, S.A. (company) — Subject company
- October 10, 2024 (date) — Filing date
FAQ
What specific changes in beneficial ownership are detailed in this amendment?
The filing is an amendment (No. 10) to a Schedule 13D, indicating a change in beneficial ownership, but the specific details of the change are not provided in the header information.
Who is the subject company of this filing?
The subject company is Procaps Group, S.A.
Who is the entity filing this amendment?
The entity filing the amendment is Hoche Partners Pharma Holding S.A.
What is the CUSIP number for the securities in question?
The CUSIP number for Procaps Group, S.A. Ordinary Shares is L7756P 102.
When was this amendment filed?
This amendment was filed on October 10, 2024.
Filing Stats: 1,139 words · 5 min read · ~4 pages · Grade level 9.7 · Accepted 2024-10-10 21:44:44
Key Financial Figures
- $0.01 — er) Ordinary Shares, nominal value of $0.01 per share (Title of Class of Securiti
Filing Documents
- procaps_13da10.htm (SC 13D/A) — 40KB
- ex99_22.htm (EX-99.22) — 14KB
- 0001019056-24-000293.txt ( ) — 56KB
of the Schedule 13D
Item 7 of the Schedule 13D is hereby amended by adding the following: Exhibit 6-K —Form 6-K filed by Procaps Group, S.A. with the Securities and Exchange Commission on October 10, 2024. Exhibit 99.22 — Letter from Hoche Partners Pharma Holding S.A. to the Board of Directors of Procaps Group, S.A. dated October 10, 2024 SIGNATURE After reasonable inquiry and to the best of the Reporting Person’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: October 10, 2024 & hoche partners pharma holding s.a. By: /s/ Roman Sokolowski Name: Roman Sokolowski Title: Director Stonehage Fleming Corporate Service Luxembourg S.A., Director By: /s/ Alexander Ludbrook - Miles Name: Alexander Ludbrook - Miles Title: Director By: /s/ Ariane Vansimpsen Name: Ariane Vansimpsen Title: Director